Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | APG101 |
Trade Name | |
Synonyms | APG-101|APG 101|Asunercept|Apocept|CAN008|CAN-008 |
Drug Descriptions |
APG101, a glycosylated fusion protein comprised of the CD95 extracellular domain and of the IgG1 Fc domain, which binds to CD95L and prevents binding to CD95, potentially leading to decreased tumor cell invasion and increased radiotherapy efficacy (PMID: 29453321, PMID: 25850884, PMID: 22446296). |
DrugClasses | |
CAS Registry Number | 1450882-18-4 |
NCIT ID | C90562 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
APG101 | APG101 | 0 | 1 |
APG101 + Radiotherapy | APG101 Radiotherapy | 0 | 0 |